Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or VSports app下载. mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2014 Jan;20(1):4-13.
doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation

Marcos de Lima  1 , David L Porter  2 , Minoo Battiwalla  3 , Michael R Bishop  4 , Sergio A Giralt  5 , Nancy M Hardy  6 , Nicolaus Kröger  7 , Alan S Wayne  8 , Christoph Schmid  9
Affiliations

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation

Marcos de Lima et al. Biol Blood Marrow Transplant. 2014 Jan.

Abstract (V体育官网入口)

In the Second Annual National Cancer Institute's Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the first relapse workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr VSports手机版. de Lima discussed pre-emptive and maintenance strategies to prevent relapse after transplantation, for example, recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction before DLI, combination of targeted agents with DLI, and considerations in use of second transplantations. Dr. Porter addressed strategies to enhance T cell function, including ex vivo activated T cells and T cell engineering, and immunomodulatory approaches to enhance T cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways. .

Keywords: Allogeneic; Prevention; Relapse; Stem cell transplantation; Treatment V体育安卓版. .

PubMed Disclaimer

"V体育2025版" Figures

Figure 1
Figure 1. Donor-Cell Consolidation of Remission for AML Relapse after AlloSCT
Analysis of EBTR data from 38 patients in CR after first-line cytoreductive therapy for relapsed AML after AlloSCT demonstrated improved OS with use of donor cells for consolidation: 55 ± 11% vs. 20 ± 10% (p=.038); DLI and second AlloSCT were considered as time-dependent variables. Adapted from: Schmid C., et al. (Blood 2012;119:1599-1606).
Figure 2
Figure 2
Theoretical relative therapeutic potential of cellular therapies for relapse. The shaded quadrant represents the zone of optimal specificity with respect to tumor vs. off-target cytotoxic tissue damage, which maximizes antitumor potency and minimizes cell-mediated morbidity. Conventional DLI and second AlloSCT (depicted in red) are the currently available cell-based treatments for relapse, against which novel therapies (blue) will be judged.
See this image and copyright information in PMC

References

    1. Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 - PMC (VSports最新版本) - PubMed
    1. Alyea EP, DeAngelo DJ, Moldrem J, et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010;16:1037–1069. - PMC - PubMed
    1. Kroger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:S94–100. - PMC - PubMed
    1. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–590. - PubMed (VSports手机版)
    1. Kroger N, Bacher U, Bader P, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010;16:1325–1346. - PubMed

Publication types (V体育2025版)

"V体育官网" MeSH terms

LinkOut - more resources (VSports最新版本)